Gastro Hep Advances
Overview
Gastro Hep Advances is a scientific journal, published since 2022 in English. The journal's country of origin is Netherlands and its primary focus area is gastroenterology.
Details
Details
Abbr.
Gastro Hep Adv
Start
2022
End
Continuing
e-ISSN
2772-5723
Country
Netherlands
Language
English
Specialty
Gastroenterology
Recent Articles
11.
Hadefi A, Leprovots M, Dinsart G, Marefati M, Vermeersch M, Monteyne D, et al.
Gastro Hep Adv
. 2025 Feb;
4(4):100599.
PMID: 39996241
Background And Aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. Though MASH is closely tied to metabolic risk factors,...
12.
Hwang S, Stoffel E, Kim D, Verna E, Zhang W
Gastro Hep Adv
. 2025 Feb;
4(4):100592.
PMID: 39996240
No abstract available.
13.
Minocha E, Jiang L, Gupta A, Green R, Zohar Y, Wertheim J
Gastro Hep Adv
. 2025 Feb;
4(4):100601.
PMID: 39996239
No abstract available.
14.
Rodriguez-Sosa A, Lawal O, McDonnell C, Grant L, OBrien J, Ali M, et al.
Gastro Hep Adv
. 2025 Feb;
4(3):100586.
PMID: 39944929
Background And Aims: Primary sclerosing cholangitis (PSC) is a progressive cholestatic disease with up to 80% of patients also suffering from ulcerative colitis (PSC-UC). The difficulty in the diagnosis along...
15.
Nieto Dominguez A, Bhurwal A, Mutneja H, Eichinger S, Pinnam B, Guifarro Rivera D, et al.
Gastro Hep Adv
. 2025 Feb;
4(3):100588.
PMID: 39944928
Background And Aims: Infliximab, widely used as a mainstay treatment of inflammatory bowel disease (IBD), is traditionally administered intravenously. The subcutaneous (SC) formulation appears to offer a more convenient route...
16.
Ying X, Zhao A, Ng N, Rosenblatt R, Lucero C, Jesudian A
Gastro Hep Adv
. 2025 Feb;
4(3):100584.
PMID: 39931049
No abstract available.
17.
Patel S, Partida D, Magee C, Garza Romero F, Chen J, Tana M, et al.
Gastro Hep Adv
. 2025 Feb;
4(3):100589.
PMID: 39931048
Background And Aims: Patient knowledge of steatotic liver disease (SLD) is suboptimal. We assessed the impact of SLD education on patient knowledge and confidence to follow provider recommendations among a...
18.
Gregersen H, Patel B, Guo X, Barron Del Solar G, Eisenstein S, Kassab G
Gastro Hep Adv
. 2025 Feb;
4(3):100580.
PMID: 39926207
No abstract available.
19.
Xue A, LaFata S, Gee T, Thel H, Cameron B, Kiran A, et al.
Gastro Hep Adv
. 2025 Feb;
4(3):100585.
PMID: 39926206
No abstract available.
20.
Yamamoto S, Kuwada T, Shiokawa M, Kitamoto H, Okabe M, Seno H
Gastro Hep Adv
. 2025 Feb;
4(3):100582.
PMID: 39926205
No abstract available.